Ian Nicholson is Chair of the Remuneration Committee. Ian has over 35 years’ international experience in management and transactions within the life sciences sector including as chairman of Bioventix plc, as operating partner at London-based Advent Life Sciences LLP, and 8 years as CEO of the privately held anti-fungal drug development company F2G Limited. Ian has worked extensively in licensing, mergers and acquisitions and market development in the UK, Europe and the USA.
Ian Nicholson
Latest news
-
LifeArc-founded RQ Bio secures £85.5 million to advance long-acting antibody for influenza prevention
-
New boost for personalised rare disease treatments as the Rare Therapies Launch Pad becomes part of LifeArc
-
World-first gene therapy to target devastating rare immune disorder